​

Inhibikase Therapeutics (IKT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IKT Stock Forecast

Inhibikase Therapeutics (IKT) stock forecast, based on 3 Wall Street analysts, predicts a 12-month average price target of $6.50, with a high of $8.00 and a low of $5.00. This represents a 132.14% increase from the last price of $2.80.

$1 $2 $3 $4 $5 $6 $7 $8 High: $8 Avg: $6.5 Low: $5 Last Closed Price: $2.8

IKT Stock Rating

Inhibikase Therapeutics stock's rating consensus is Buy, based on 3 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (66.67%), 1 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 3 1 2 0 Strong Sell Sell Hold Buy Strong Buy

IKT Forecast vs Benchmarks

TypeNameUpside
StockInhibikase Therapeutics132.14%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$8.00$6.50
Last Closing Price$2.80$2.80$2.80
Upside/Downside-185.71%132.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2521---3
Dec, 2421---3
Nov, 2422---4
Oct, 2422---4
Sep, 2422---4
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 08, 2024Dennis DingJefferies$8.00$2.78187.77%185.71%
Oct 11, 2024Edward WhiteH.C. Wainwright$5.00$1.42252.11%78.57%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 08, 2024JefferiesBuyinitialise
Oct 11, 2024H.C. WainwrightBuyBuyhold
Aug 16, 2024H.C. WainwrightBuyBuyhold
May 21, 2024H.C. WainwrightBuyBuyhold
Nov 16, 2022JonesTradingHolddowngrade

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.88$-4.26$-3.57-----
Avg Forecast$-4.68$-4.44$-2.76$-0.90$-0.45$-0.56$-0.16$0.32
High Forecast$-4.68$-4.44$-2.76$-0.90$-0.46$-0.77$-0.28$0.32
Low Forecast$-4.68$-4.44$-2.76$-0.89$-0.44$-0.29$-0.04$0.32
Surprise %4.27%-4.05%29.35%-----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.10M$123.44K$260.50K-----
Avg Forecast$3.40M$100.00K$280.50K$1.00$353.85K$8.64M$20.36M$164.29M
High Forecast$3.40M$100.00K$280.50K$1.00$353.85K$8.64M$20.36M$164.29M
Low Forecast$3.40M$100.00K$280.50K$1.00$353.85K$8.64M$20.36M$164.29M
Surprise %-8.81%23.44%-7.13%-----

Net Income Forecast

$-25M $-19M $-13M $-7M $-1M $5M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-14.81M$-17.91M$-19.03M-----
Avg Forecast$-24.96M$-23.68M$-14.69M$-4.79M$-2.42M$-2.83M$-853.30K$1.71M
High Forecast$-24.96M$-23.68M$-14.69M$-4.82M$-2.47M$-4.11M$-1.47M$1.71M
Low Forecast$-24.96M$-23.68M$-14.69M$-4.77M$-2.37M$-1.55M$-233.38K$1.71M
Surprise %-40.68%-24.38%29.51%-----

IKT Forecast FAQ

Is Inhibikase Therapeutics stock a buy?

Inhibikase Therapeutics stock has a consensus rating of Buy, based on 3 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Inhibikase Therapeutics is a favorable investment for most analysts.

What is Inhibikase Therapeutics's price target?

Inhibikase Therapeutics's price target, set by 3 Wall Street analysts, averages $6.5 over the next 12 months. The price target range spans from $5 at the low end to $8 at the high end, suggesting a potential 132.14% change from the previous close price of $2.8.

How does Inhibikase Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Inhibikase Therapeutics stock forecast shows a 132.14% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Inhibikase Therapeutics over the past three months?

  • January 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Inhibikase Therapeutics’s EPS forecast?

Inhibikase Therapeutics's average annual EPS forecast for its fiscal year ending in December is -0.9 for 2024, a -74.79% decrease from the reported $-3.57 in 2023. The prediction for 2025 is $-0.45, $-0.56 for 2026, $-0.16 for 2027, and $0.32 for 2028.

What is Inhibikase Therapeutics’s revenue forecast?

Inhibikase Therapeutics's average annual revenue forecast for its fiscal year ending in December is $1 for 2024, a -100.00% decrease from the reported $260.5K in 2023. The forecast for 2025 is $353.85K, $8.64M for 2026, $20.36M for 2027, and $164.29M for 2028.

What is Inhibikase Therapeutics’s net income forecast?

For its fiscal year ending in December, Inhibikase Therapeutics's average annual net income forecast is $-4.793M for 2024, reflecting a -74.81% decrease from the reported $-19.029M in 2023. The projection for 2025 is $-2.418M, $-2.827M for 2026, $-853K for 2027, and $1.71M for 2028.